Antagonism of botulinum toxin A-mediated muscle paralysis by 3,4-diaminopyridine delivered via osmotic minipumps

Toxicon

Volumn 38, Issue 10, 2000, Pages 1381-1388

  Adler, Michael ^a   Capacio, Benedict ^a   Deshpande, Sharad S ^a  

^a U S ARMY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; BOTULINUM TOXIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG INFUSION; EXTENSOR DIGITORUM LONGUS MUSCLE; LD 50; MALE; MUSCLE TWITCH; NEUROMUSCULAR TRANSMISSION; NONHUMAN; OSMOTIC MINIPUMP; PARALYSIS; PRIORITY JOURNAL; RAT;

4-AMINOPYRIDINE; ANIMALS; BOTULINUM TOXIN TYPE A; DRUG DELIVERY SYSTEMS; HINDLIMB; INFUSION PUMPS, IMPLANTABLE; MALE; MUSCLE CONTRACTION; MUSCLE, SKELETAL; ORGAN SIZE; PARALYSIS; POTASSIUM CHANNEL BLOCKERS; RATS;

EID: 0034025358     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-0101(99)00231-7     Document Type: Article

References (18)

1. Adler M., Deshpande S.S., Foster R.E., Maxwell D.M., Albuquerque E.X. Effects of subacute pyridostigmine administration on mammalian skeletal muscle function. J. Appl. Toxicol. 12:1992;25-33.
2. Adler M., Scovill J., Parker G., Lebeda F.J., Piotrowski J., Deshpande S.S. Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. Toxicon. 33:1995;527-537.
3. Adler M., Macdonald D.A., Sellin L.C., Parker G.W. Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Toxicon. 34:1996;237-249.
4. Brown M.C., Holland R.L., Hopkins W.G. Motor nerve sprouting. Annu. Rev. Neurosci. 4:1981;17-42.
5. Byers C.E., Whalley C.E., Capacio B.R. Pharmacokinetics and tissue distribution of 4-aminopyridine and 3,4-diaminopyridine in guinea pigs. FASEB J. 12:1998;A143.
6. Capacio B.R., Byers C.E., Matthews R.L., Chang F.-C.T. A method for determining 4-aminopyridine in plasma: pharmacokinetics in anesthetized guinea pigs after intravenous administration. Biomed. Chrom. 10:1996;111-116.
7. Cherington M. Botulism: 10-year experience. Arch. Neurol. 30:1974;432-437.
8. Ferrer-Montiel A.V., Gutiérrez L.M., Apland J.P., Canaves J.M., Gil A., Viniegra S., Biser J.A., Adler M., Montal M. The 26-mer peptide released from SNAP-25 cleavage by botulinum neurotoxin E inhibits vesicle docking. FEBS Lett. 435:1998;84-88.
9. Huang X., Wheeler W., Kang Y., Sheu L., Lukacs G., Trimble W., Gaisano H. Truncated SNAP-25 (1-197), like botulinum neurotoxin A, can inhibit insulin secretion from HIT-T15 insulinoma cells. Mol. Endocrinol. 12:1998;1060-1070.
10. Keller J.E., Neale E.A., Oyler G., Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 456:1999;137-142.
11. Molgo J., Lundh H., Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effects of pH changes. Eur. J. Pharmac. 61:1980;25-34.
12. Niemann H., Blasi J., Jahn R. Clostridial neurotoxins: new tools for dissecting exocytosis. Trends Cell Biol. 4:1994;179-185.
13. Otto H., Hanson P.I., Chapman E.R., Blasi J., Jahn R. Poisoning by botulinum neurotoxin A does not inhibit formation or disassembly of the synaptosomal fusion complex. Biochem. Biophys. Res. Commun. 212:1995;945-952.
14. Schiavo G., Santucci A., DasGupta B.R., Mehta P.P., Jontes J., Benfenati F., Wilson M.C., Montecucco C. Botulinum neurotoxin serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 335:1993;99-103.
15. Sellin L.C., Thesleff S., DasGupta B.R. Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction. Acta Physiol. Scand. 119:1983;127-133.
16. Simpson L.L. A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism. Infect. Immun. 52:1986;858-862.
17. Vaidyanathan V.V., Yoshino K., Jahnz M., Dörries C., Bade S., Nauenburg S., Niemann H., Binz T. Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J. Neurochem. 72:1999;327-337.
18. Van Lunteren E., Moyer M. Effects of DAP on diaphragm force and fatigue, including fatigue due to neurotransmission failure. J. Appl. Physiol. 81:1996;2214-2220.